ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,212.20
0.10%
S&P ASX All Technology
3,444.90
0.35%
Brent Oil
71.21
0.37%
US Dollar vs AUD
1.44382
-0.49%
Bitcoin
66,297.34
1.71%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Allarity Therapeutics Inc (ALLR)

  7. Allarity Therapeutics Inc (ALLR) News

ALLR

Allarity Therapeutics (ALLR)

Allarity Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALLR
DateTimeSourceHeadlineSymbolCompany
19/09/202406:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALLRAllarity Therapeutics Inc
17/09/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
16/09/202422:00GlobeNewswire Inc.Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer TrialNASDAQ:ALLRAllarity Therapeutics Inc
13/09/202422:53Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
13/09/202422:45GlobeNewswire Inc.Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALLRAllarity Therapeutics Inc
11/09/202422:00GlobeNewswire Inc.Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)NASDAQ:ALLRAllarity Therapeutics Inc
10/09/202423:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALLRAllarity Therapeutics Inc
10/09/202406:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
09/09/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
31/08/202406:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALLRAllarity Therapeutics Inc
30/08/202407:57Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ALLRAllarity Therapeutics Inc
22/08/202406:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
06/08/202407:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLRAllarity Therapeutics Inc
26/07/202423:00GlobeNewswire Inc.Allarity Therapeutics Announces Postponement of Annual Stockholders MeetingNASDAQ:ALLRAllarity Therapeutics Inc
26/07/202420:04Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALLRAllarity Therapeutics Inc
24/07/202420:00GlobeNewswire Inc.Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized SharesNASDAQ:ALLRAllarity Therapeutics Inc
24/07/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
22/07/202420:30GlobeNewswire Inc.Allarity Therapeutics Outlines Company’s 2024 Progress and ObjectivesNASDAQ:ALLRAllarity Therapeutics Inc
22/07/202420:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
27/06/202422:00GlobeNewswire Inc.Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining ComplianceNASDAQ:ALLRAllarity Therapeutics Inc
25/06/202422:00GlobeNewswire Inc.Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
06/06/202422:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
24/05/202422:55Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALLRAllarity Therapeutics Inc
21/05/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
20/05/202422:00GlobeNewswire Inc.Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementNASDAQ:ALLRAllarity Therapeutics Inc
18/05/202406:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
15/05/202423:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
15/05/202406:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLRAllarity Therapeutics Inc
15/05/202406:01GlobeNewswire Inc.Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity BalancesNASDAQ:ALLRAllarity Therapeutics Inc
10/05/202401:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALLR

Your Recent History

TSX
CTF.UN
Citadel Income
AMEX
XTV
BIT
P21GM1
NLBNPIT21GM1 20351221 25...
USOTC
DTTOF
DITO CME (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved